Medications such as Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i), Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), and the novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, tirzepatide, have revolutionized diabetes treatment paradigms (Table 1). This evidence concerns the gene SLC5A2 and diabetes mellitus.